Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Molecular NeuroImaging

Request full access

Specialized imaging and eClinical solutions for biopharmaceuticals

New Haven, United StatesFounded 2000Biotech & Life Sciences

About Molecular NeuroImaging

Perceptive offers specialized support for global pharmaceutical, biotech, and clinical research organizations across the entire R&D lifecycle. The company's services include imaging biomarkers, core lab services, and technologies for randomization and trial supply management (RTSM). The entity known today as Perceptive has a complex history involving several strategic mergers, acquisitions, and rebrandings. The journey begins with companies like Molecular NeuroImaging (MNI), Perceptive Informatics, and PAREXEL. MNI was founded in 2000 by Ken Marek and John Seibyl, specializing in neuroimaging services for drug development. Perceptive Informatics operated as a subsidiary of PAREXEL International, providing a suite of eClinical solutions including medical imaging, RTSM, and clinical trial management systems (CTMS). In 2016, inviCRO, a provider of imaging services, acquired MNI to create a full-service translational imaging provider. A year later, in 2017, Pamplona Capital Management acquired PAREXEL International, which included its Perceptive Informatics division. In January 2021, PAREXEL separated its Informatics and Medical Imaging business, which was then launched as an independent company named Calyx. Calyx was subsequently acquired by GLO Healthcare, a platform created by CapVest Partners. Later, Calyx acquired inviCRO, further expanding its biomarker capabilities. In February 2024, Ennov acquired the 'Enterprise Technology' division from Calyx, which included its regulatory information management solutions. Finally, in September 2024, the remaining Calyx and inviCRO businesses rebranded to become Perceptive. Perceptive operates on a business-to-business model, serving biopharmaceutical and clinical research organizations. Its revenue is generated by providing a range of services and technology solutions that support clinical trials from the preclinical phase to post-marketing. These offerings are structured into several key areas: Perceptive Discovery for preclinical imaging, Perceptive eClinical for trial management technologies like IRT/RTSM, and Perceptive Imaging which serves as an imaging core lab for clinical trials. The company has supported over 400 regulatory approvals and has a global presence with offices in North America, Europe, and Asia.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2000
Headquarters
New Haven, United States
Employees
1,286
Open positions
None listed
Dealroom signal
37.0/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Biomarkers, Clinical, Medical Imaging, Techbio, DT and LS
Technology
Big Data, Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jan 2026 $15M $60M CapVest ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Molecular NeuroImaging website traffic

Latest recorded traffic for Molecular NeuroImaging is 23K monthly website visits, down 8% over the last three months.

Latest monthly visits23K 3-month web change-8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Molecular NeuroImaging in the New Haven ecosystem

Live from Dealroom

The Molecular NeuroImaging office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • CapVest
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
19 countries with
team presence
🇮🇳 India38.6%
🇺🇸 United States29.6%
🇬🇧 United Kingdom24.3%
🇩🇪 Germany2.5%
🇨🇳 China1.9%
Top 5 of 19 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Molecular NeuroImaging on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Molecular NeuroImaging’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.